ArticleBMC cardiovascular disorders2026
Diagnostic and pathophysiological significance of serum myeloperoxidase, ischemia-modified albumin, paraoxonase-1 and galectin-3 in COVID-19 - parallels with myocarditis.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID-19 has emerged as a complex disease extending beyond respiratory involvement and is characterized by systemic inflammation and oxidative stress, which may also affect the cardiovascular system. Our study sought to elucidate the function of biomarkers serum myeloperoxidase (MPO), ischemic modified albumin (IMA), paraoxonase-1 (PON-1) and galectin-3 (GAL-3) in the pathophysiology of COVID-19 to explore their potential associations with pathophysiological mechanisms commonly involved in myocardial injury.
methodsOur prospective case-control study assessed biomarker discrimination between hospitalized COVID-19 patients and healthy controls. Serum levels of biomarkers were measured using ELISA and enzymatic reaction products were assessed using spectrophotometric methods.
resultsOur findings showed that serum MPO, IMA, and GAL-3 levels were significantly higher in the COVID-19 group compared with control, while PON-1 levels were significantly lower. Subgroup analyses based on disease severity revealed that changes in these biomarkers were more pronounced in patients with severe COVID-19.
conclusionsThe significant increase in GAL-3 and MPO levels in severe cases supports the role of inflammatory burden and oxidative stress in disease progression, while the decrease in PON-1 levels indicates a decrease in antioxidant defense capacity. Overall, these findings indicate the presence of shared pathophysiological mechanisms between COVID-19 and myocardial injury, rather than providing direct evidence of myocarditis. The observed biomarker alterations are compatible with mechanisms implicated in myocarditis and may be of interest for future myocarditis research; however, direct evaluation in well-characterized myocarditis cohorts is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.